Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
about
New genetic associations detected in a host response study to hepatitis B vaccinePre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccineHost genetic factors and vaccine-induced immunity to HBV infection: haplotype analysisA vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production.Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1CD3Z genetic polymorphism in immune response to hepatitis B vaccination in two independent Chinese populationsHepatitis B vaccination and associated oral manifestations: a non-systematic review of literature and case reports.Infection and vaccination in chronic fatigue syndrome: myth or reality?Physicians infrequently adhere to hepatitis vaccination guidelines for chronic liver disease.Sleep and antibody response to hepatitis B vaccination.Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.Persistence of Anti-HBs Among Palestinian Medical Students After 18 - 22 Years of Vaccination: A Cross-Sectional Study.HLA-DR: molecular insights and vaccine design.Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide surveyImmune Responses to Single-Dose Versus Double-Dose Hepatitis B Vaccines in Healthcare Workers not Responding to the Primary Vaccine Series: A Randomized Clinical TrialFunctionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations.Vaccinating Adult Patients with Cirrhosis: Trends over a Decade in the United States.Ever closer to a prophylactic vaccine for HCV.Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progressSendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsPotential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon.Vaccines and biosimilarity: a solution or a problem?The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg)" serological profile.Update on Chlamydia trachomatis Vaccinology.Vaccination against infection in patients with multiple sclerosis.Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen.Seroprevalence of hepatitis B and C among domestic and healthcare waste handlers in Belo Horizonte, Brazil.Response to hepatitis B vaccination in patients with liver cirrhosis.Polymorphisms in IRG1 gene associated with immune responses to hepatitis B vaccination in a Chinese Han population and function to restrain the HBV life cycle.Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens.Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency.Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster.Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination.Role of T-regulatory cells in the response to hepatitis B vaccine in hemodialysis patients.A double-dose hepatitis B vaccination schedule in travelers presenting for late consultation.A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations.
P2860
Q28276283-2B798F53-1F89-40E3-9A80-C797BDDD0D5DQ33359620-054F1FCA-2672-4F69-A7CF-2D2674187A9EQ33678959-5B209B10-A13D-4DB9-AF97-7B6AFD63E947Q33964081-E6097EBE-33F4-4009-91F8-4F7B695D9716Q34034063-B08CC882-5404-4C71-815E-A436A167C10DQ34175747-70C45F83-8649-48D8-AC71-B0134183F4F9Q34247198-0E49171E-D641-4B51-B3F2-0286E70EBED2Q34606667-50A82B90-7C65-4F0E-B7C2-F3F7A4864742Q34609090-3A7EA3E7-5A63-468A-BEE3-FAFDA41115D1Q34907938-3821670D-8431-4EE5-A2C3-4838E1C07867Q36097807-4D78E2C4-D861-4412-871E-B056E706F62DQ36281860-5B7199C7-1EF8-4E66-BEEA-0BC941F08E68Q36474957-771EFB01-9929-4473-B9B0-C5015E41EBCBQ36737531-AA335FC7-83AC-4D64-BCCD-9CFD59A4FC37Q36769147-5679D6BF-7A4F-4641-BE6C-F94DBD250EC5Q36854656-ECAD08E5-F8AD-425A-A813-776B96B5B9C6Q36899068-6B63F65E-86A0-43D8-A9D1-97732F19C197Q36901395-D097BF97-63EB-4D1A-97AB-7B8538856143Q37089122-EB167108-3C63-462C-BB90-B802A74AEBD9Q37159670-A8DD8423-D095-4650-8C9E-926E36E4EA13Q37308711-00CC9BA9-C36A-4374-86E2-6928752AE475Q37345255-05323931-866F-420B-8708-3CA28DD1CC81Q37608322-F20CE188-D064-41BC-A5DC-6C3EE9950DDEQ37748557-E48064A5-67E7-483E-B9CB-E7A61A3C1EBDQ37834874-604AC29A-ADE5-406C-8D19-95F7A93F8442Q37978121-C56C8D10-83D2-49A9-A7A9-47DDAB1DE95CQ38306933-87D62D94-3336-46F7-BE8A-CCA789D16620Q38693411-365C5042-FB69-413F-AA7F-D700D173C000Q39260718-2801A20E-11C4-4CE0-A3E5-C15189516E5BQ40047095-F8BE9E04-4E96-4F52-990F-BF5571222E37Q40399420-083CC36A-B4BA-40B4-8FC7-CE04364E7B72Q40427997-05849586-F870-43B1-AE67-DD6694B4F95BQ40436367-CAC3D50A-060F-4210-9A9D-2FDFB2AD1B41Q40440788-E9CC19D3-D9F2-4668-83AA-95F0E14CE239Q40500488-5AE8492E-EB6F-4DFB-9760-3720F5B63877Q40609175-83DCFD2B-27D6-44CB-AD93-5740740ADCBDQ41128684-BFE78C86-C56A-48C7-8230-AA0535491A41Q41143293-F69EEA9A-76E4-4655-BE3A-B0E2BF7274E8Q42220517-DE903E90-169D-49D7-B48B-EA6ADBCA0406Q42252783-7B333EC1-21A9-4C5B-B7C5-26CED69C267C
P2860
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@ast
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@en
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@nl
type
label
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@ast
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@en
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@nl
prefLabel
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@ast
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@en
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@nl
P2860
P356
P1476
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
@en
P2093
Jane N Zuckerman
P2860
P304
P356
10.1002/JMV.20524
P577
2006-02-01T00:00:00Z